Alerta

阿尔茨海默相关神经丝蛋白检测试纸条、其制备方法及应用

Resumen de: CN121831160A

本发明公开了一种阿尔茨海默相关神经丝蛋白检测试纸条、其制备方法及应用，包括：底板，以及沿第一端向第二端的方向依次设置在所述底板上的双层样品垫、结合垫、硝酸纤维素膜和吸水垫；其中，沿第一端向第二端的方向为待测样品在该试纸条上的流动方向；本发明的试纸条中的双层样品垫由分别采用不同方式处理的两层聚酯纤维膜搭接形成，结合垫上喷涂有不同粒径的乳胶微球混合物与抗体偶联得到的标记物，且偶联方法采用低温超声偶联法，通过以上对试纸条制备方法的改进，使得本发明制备得到的试纸条具有抗基质干扰能力强、检测准确性高、灵敏度高、线性范围广、检测速度快、稳定性强、检测结果可肉眼可视化判读，适用于AD大规模早筛等优势。

一种抗重组sCD40L的鼠源单克隆抗体及其制备方法与用途

Resumen de: CN121824765A

0001 本发明公开了一种抗重组sCD40L的鼠源单克隆抗体及其制备方法与用途，属生物医药领域。本发明以重组sCD40L免疫BALB/c小鼠，经杂交瘤技术获4株稳定分泌单抗的细胞株HYD‑5048‑01至04，单抗亚型为IgG1/κ和IgG2b/κ，Kd值达nM级，重、轻链可变区序列（SEQ ID NO.1‑16）为全新序列。经ELISA、Western blot及免疫组化验证，所有单抗均可特异性结合sCD40L。其中，5048‑02的F(ab')2片段（DT1）可减轻血栓及器官纤维化症状；5048‑03靶向血栓性疾病；5048‑02/04对神经退行性疾病、自身免疫病及器官移植排斥有防治潜力。本发明提供的单抗兼具高特异性和强亲和力，为相关药物研发提供全新工具。

基于梯度核酸编码和毛细管电泳的多组学联检方法和进行该方法的系统

Resumen de: CN121831127A

本申请公开了基于梯度核酸编码和毛细管电泳的多组学联检方法和进行该方法的系统。基于梯度核酸编码和毛细管电泳的多组学联检方法包括以下步骤：设计长度和序列均不相同的多个寡核苷酸对；制备标记探针对；反应杂交形成寡核苷酸对；生成对应于待测物的DNA模板；产生带有标记物的、长度各异的DNA扩增产物；制备毛细管电泳谱图；鉴定出对应的待测物种类；和/或，对相应的待测物进行定量分析。该方法在临床诊断、生物标志物发现、蛋白质、基因和代谢组学等生命科学研究中具有广泛的应用前景。

一种基于血浆神经元来源外泌体在抑郁症诊断中的应用

Resumen de: CN121831145A

本发明公开了一种基于血浆神经元来源外泌体在抑郁症诊断中的应用，利用血浆提取神经元来源外泌体检测血清中的 NDEVs 并检测 USP11水平，发现抑郁症患者的 NDEVs 中 USP11 显著高于健康对照，因此血清中的 NDEVs中 USP11水平可以反映颅内神经细胞状态的生物状态，该检测在抑郁症的诊断中能够显著提高检测特异性和敏感度，具有很高的临床应用价值。

認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置

Resumen de: US11826321B2

0001 Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.

特发性常压脑积水生物标志物、诊断试剂盒及应用

Resumen de: CN121831168A

本发明公开了特发性常压脑积水生物标志物、诊断试剂盒及应用，属于生物医药技术领域，尤其涉及一种特发性常压脑积水生物标志物，所述生物标志物为蛋白质生物标志物，包括NBL1、TREM2、COL3A1、DPP7、PLA1A、SELENBP1、FGB、CCK、WFIKKN2、KNG1、HBA2、GFRA3、CSF1。特发性常压脑积水生物标志物在制备特发性常压脑积水诊断试剂盒中的应用。本发明通过DIA技术筛选差异蛋白，PRM技术验证蛋白表达，筛选得到了特发性常压脑积水生物标志物，用于iNPH的早期筛查、风险评估和预后判断，实现了对iNPH的早期、准确、客观诊断，缩短临床诊断周期，提升诊疗效率。

血浆中NEV/OEV的荧光值在辅助鉴别帕金森病和多系统萎缩中的应用

Resumen de: CN121831157A

0001 本发明涉及血浆中NEV/OEV的荧光值在辅助鉴别帕金森病和多系统萎缩中的应用。包括以下步骤：以NEV/OEV作为辅助鉴别PD和MSA的诊断指标，其中，NEV为RT‑QuIC实验中得到NEV反应终点荧光信号最大值，OEV为RT‑QuIC实验中得到OEV反应终点荧光信号最大值。与现有技术相比，本发明首次使用外周血结合α‑syn扩增技术来鉴别鉴别PD和MSA，实现PD与MSA的高效鉴别，填补了外周血中外泌体结合α‑syn扩增技术鉴别两种疾病的空白。

改良された血液診断

Resumen de: WO2024200207A1

A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.

ペプチジルグリシンα－アミド化モノオキシゲナーゼ（ＰＡＭ）の測定法及び診断目的のためのその使用

Resumen de: JP2026510789A

本発明は、ＰＡＭの立体構造エピトープに対する少なくとも１つの結合剤を含むアッセイを使用して、体液又は組織試料中のＰＡＭ及び／又はそのアイソフォーム及び／又はその断片のレベルを決定するための方法、並びに診断目的のためのその使用を対象とする。【選択図】なし

腸透過性を判定するための方法

Resumen de: WO2024189211A1

The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.

LRP1-β链短肽作为靶标在治疗主动脉夹层中的应用

Resumen de: CN121818897A

本发明公开了编码LRP1‑β链短肽的基因作为靶标在筛选/制备治疗主动脉夹层的药物中的应用，诱导LRP1‑β链短肽过表达的试剂在制备治疗主动脉夹层的药物中的应用，以及LRP1‑β链短肽作为生物标志物在制备主动脉夹层诊断试剂中的应用。通过实验首次证明了LRP1‑β链短肽可通过下调OPN的表达抑制血管平滑肌细胞表型转化和巨噬细胞炎症浸润，减轻炎症反应，可缓解或抑制主动脉夹层发生发展，为主动脉夹层的治疗提供了新的方向和思路，有望应用在治疗主动脉夹层的新药研发中。

SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF

Resumen de: US20260098070A1

0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.

TREATED DRIED BLOOD SAMPLE FOR DETECTION OF HEAVY METALS IN DRIED BLOOD

Resumen de: US20260098855A1

0000 The present invention provides methods, compositions, kits, and devices for detecting heavy metals in dried blood (e.g., dried blood spots). For example, the present invention provides: 1) dried blood spot paper that is detectably free of heavy metals and methods of preparing such paper using organic acid; 2) dried blood extraction solutions optimized for heavy metal detection (e.g., extraction solutions containing acetic acid and/or gold); 3) methods for estimating venous blood volume from dried blood mass; and 4) kits and kit components optimized for heavy metal detection in dried blood (e.g., kits with paper detectably free of heavy metals, heavy metal free skin wipes, metal free collection case, etc.).

BIOMARKERS IN LONG-COVID-19

Resumen de: US20260098868A1

A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.

INFLAMMATORY DISEASE GENE PANEL

Resumen de: US20260098305A1

Provided is a method of determining whether a patient has bladder cancer, colon cancer, or breast cancer. Also provided is a method of determining whether a patient has a chronic inflammatory disease. Additionally provided is a method of evaluating patient response to a treatment for a chronic inflammatory disease. Further provided is a method of developing a treatment for a chronic inflammatory disease in a patient.

METHOD OF DETERMINING THE HEALTH STATUS OF A DOG

Resumen de: AU2024370445A1

The present invention provides a method for determining a biological age, mortality risk and/or probability of a healthy lifespan of a dog; said method comprising: a) determining a biological age, mortality risk and/or probability of a healthy lifespan of the dog using the level of one or more biomarker(s) in one or more samples obtained from the dog, wherein the one or more biomarker(s) is selected from white blood cell count, serum albumin, serum alkaline phosphatase, serum creatine kinase, haemoglobin, haematocrit, mean corpuscular haemoglobin, serum glucose, mean red cell volume, serum globulin, serum calcium, platelet count, and/or red blood cell count; and b) determining a biological age, mortality risk and/or probability of a healthy lifespan for the dog using a DNA methylation profile from the dog.

A METHOD FOR CLASSIFYING A SUBJECT AS HIGH-RISK FOR NEUROLOGICAL OR PSYCHIATRIC DISORDER

Resumen de: WO2026074061A1

In the present invention provided is a method for classifying a subject as a high-risk for neurological or psychiatric disorder subject. The method is particularly useful when the neurological or psychiatric disorder is selected from the group containing schizophrenia, psychosis, mood disorder, depression (such as major depressive disorder), bipolar disorder, Alzheimer's disease, Parkinson disorder, and cognitive impairment. The present invention further relates to a biomarker kit comprising reagents for determining expression level of biomarkers for extracellular vesicles, brain-derived extracellular vesicles and biomarkers for mitochondrial and redox impairment, N-methyl-D-aspartate receptor pathway, and other pathways related to central nervous system disorders.

COMPOSITIONS AND METHODS FOR MODULATING NEURAL ACTIVITY

Resumen de: WO2026076419A1

Provided herein are, inter alia, methods and compositions for transfecting a brain cell (e.g., neuron). The methods for transfecting a brain cell provided herein including embodiments thereof include, for example, transfecting the brain cell with a viral vector encoding a potassium-selective light-sensitive protein (e.g., kalium channelrhodopsin). Also provided herein are, inter alia, methods of modulating a neural network of brain cells (e.g., neurons) by activating a potassium-selective channelrhodopsin with light. The methods and compositions provided herein are, inter alia, useful for treating neurological or psychiatric diseases or disorders (e.g., epilepsies, Parkinson's disease, Alzheimer's, etc.).

METHODS OF IDENTIFYING SUBJECTS SUFFERING FROM MULTIPLE SYSTEM ATROPHY OR PARKINSON'S DISEASE BY ALPHA-SYNUCLEIN SEEDED AGGREGATION ASSAYS (SAA)

Resumen de: WO2026073942A1

The present invention relates to methods of identifying subjects suffering from Multiple System Atrophy (MSA) or Parkinson's Disease (PD). The method comprises subjecting a biological sample obtained from a subject to a seeded aggregation assay or a sequence of seeded aggregation assays. The invention also further provides methods of treating the identified MSA patient or the PD patient with compounds capable of inhibiting alpha synuclein aggregation.

SYSTEMS AND METHODS FOR BIOMARKER DETECTION

Resumen de: WO2026076034A2

Provided herein are systems, compositions, and methods for detecting analytes (e.g., proteins, nucleic acid molecules, biomolecules, peptides, antibodies, biomarkers). In an aspect, a method for analyte detection, comprising: (a) providing: (i) a first probe coupled to a surface of a substrate, and (ii) said analyte; (b) binding said first probe coupled to said surface of said substrate and a second probe to said analyte, to generate a complex; (c) using said first probe and said second probe of said complex to generate a reaction product; and (d) detecting said analyte using said reaction product.

METHOD OF DETECTING AUTOANTIBODIES AGAINST FC EPSILON RECEPTOR I

Resumen de: WO2026074476A1

The present disclosure relates to methods of detecting a target ligand in a sample, wherein the target ligand is capable of inducing oligomerization and/or cross-linking of the target ligand's receptor, and uses of the method thereof.

COMPOSITIONS AND METHODS FOR IN VIVO DETECTION, DIAGNOSIS AND TREATMENT OF A DISEASE OR A DISORDER

Resumen de: WO2026076310A1

The present disclosure relates to synthetic probes and methods of using the synthetic probes. The synthetic probes include a binding domain that specifically binds a target, a cleavable linker, and a reporter. Cleaving the linker releases the reporter after a sufficient time following administration of a cleaving agent allowing for collection of the released reporter in a sample from the subject. The synthetic probes and methods can be used to diagnose a disease or disorder in a subject having or suspected of having a disease or disorder and for treating a disease or disorder.

EXOSOME ISOLATION METHOD

Resumen de: WO2026075627A1

Process of the invention, utilizes L-arginine-coated magnetic nanobeads for exosome isolation. pre-processing steps consisting of filtration and low-speed centrifugation enrich exosome- containing samples, allowing for more economical use of magnetic beads in subsequent stages compared to the initial sample volume.

A field-effect transistor based biosensor having an electrode insulation layer.

Resumen de: KR20260047788A

본 발명은 전해질을 게이트 절연층으로 사용하는 트랜지스터 기반 바이오 센서에 있어서, 전극 표면에 자기조립 다층 분자막으로 이루어진 전극 절연층을 구비함으로써 전기 누전에 의한 전극의 단락을 방지하고 우수한 패시베이션 효과를 구현할 수 있고, 나아가 표적 물질을 정확하고 신속하게 검출할 수 있는 전극 절연층을 갖는 전계효과 트랜지스터 기반 바이오 센서에 관한 것이다.

A field-effect transistor based biosensor having an electrode insulation layer.

Nº publicación: KR20260047787A 09/04/2026

Solicitante:

경기대학교산학협력단

Resumen de: KR20260047787A

본 발명은 전해질을 게이트 절연층으로 사용하는 트랜지스터 기반 바이오 센서에 있어서, 전극 표면에 자기조립 다층 분자막으로 이루어진 전극 절연층을 구비함으로써 전기 누전에 의한 전극의 단락을 방지하고 우수한 패시베이션 효과를 구현할 수 있는 전극 절연층을 갖는 전계효과 트랜지스터 기반 바이오 센서에 관한 것이다.